ARAnthony S. Russell

Anthony S. Russell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anthony S. Russell has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Relative Efficacies: Antimalarials to Abatacept - The Choice Is Ours

    by Anthony S. Russell

    Early diagnosis and treatment of rheumatoid arthritis (RA) are important in order to halt disease progression and joint destruction, and minimize loss of function. Individually, the disease modifying antirheumatic drugs have demonstrated similar efficacies in radiological and clinical outcomes. However, various combination therapies have been shown to improve therapeutic outcomes for patients who fail to respond adequately to monotherapy. With the introduction of the cytokine inhibitors and the development of newer biologic therapies, a number of treatment options are available for patients with RA. The efficacies of the various treatment strategies are reviewed.

  • Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

    by A S Russell, G V Wallenstein, T Li, M C Martin, R Maclean, B Blaisdell, K Gajria, J C Cole, J-C Becker, P Emery

    Objective: To examine the impact of added abatacept treatment on health related quality of life (HRQoL) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX). Methods: The impact of abatacept treatment on HRQoL was examined in a longitudinal, randomised double blind, placebo controlled clinical trial. Effects of treatment on HRQoL were examined using repeated measures analysis of covariance and comparing rates of change in HRQoL across treatment groups. The relationship between American College of Rheumatology (ACR) clinical markers and disease duration with changes in HRQoL indicators was also examined. Finally, a responder analysis was used to examine the percentage of patients who improved by 0.5 SD in 12 months or who reached the normative levels seen in the US general population. Results: Statistically significant improvements in the abatacept group relative to controls were observed across a range of HRQoL measures, including physical function, fatigue, all eight domains of the SF-36, and the physical and mental component summaries (PCS and MCS). Improvements were seen as early as day 29 for fatigue and for five out of eight SF-36 domains. By day 169, all HRQoL measures were significantly better with abatacept than with placebo. HRQoL gains were associated with greater ACR clinical improvement, and the effects were consistent for patients with different disease duration. A significantly greater percentage of patients treated with abatacept reached normative levels of PCS, MCS, physical functioning, and fatigue compared with patients treated with MTX alone. Conclusion: Combined abatacept and MTX treatment produces significant improvements across a wide range of HRQoL domains in patients with RA.


  • An assessment of the new ''SCORE'' index as a predictor of osteoporosis in women

    by Robert T. Morrison Anthony S. Russell

    Background: The study was done to determine whether the new SCORE (Simple Calculated Osteoporosis Risk Estimation) index might reduce the utilization of bone mineral density (BMD) measurement. Methods: 989 consecutive patients who were referred by a range of physicians for BMD assessments at one of two clinics had a SCORE index constructed. Approximately 95% of the subjects were Caucasian. The index is based on only 6 factors: age, previous fractures, rheumatoid arthritis, estrogen use, weight, and race. Results: All but 1 (0.1%) of those with a femoral neck BMD T-score of <-2.5 had an abnormal SCORE index. However, its specificity was relatively low, since two thirds of those individuals also with an abnormal index had a T-score of >-2.5. One percent false negatives were also seen in the lumbar spine. Conclusion: The SCORE index correctly predicted those individuals who did not have an osteoporotic T-score. It was of the most value in the Discussion: The precise role of BMD measurement in the assessment and management of individuals possibly at risk for osteoporosis remains controversial. Our results suggest that the prior use of the SCORE index by the referring physicians to screen the patients sent for BMD measurement would have allowed them to exclude over 20% of the patients referred for assessment, and therefore reduce the need and cost of BMD measurement. The proportion of individuals who had a normal SCORE index, and would have been screened out, was 43% in the under 60 year age group, but in the 65 and over age group it provided no additional information to help with, for example, the National Osteoporosis Foundation (NOF) guidelines.


    • 1 August 1998
      • Vol. 25  (8) , 1634-7

    WHO/ILAR/IFSSD workshop on osteoporosis.

    by A S Russell, S Recart, J Y Reginster, R Arinoviche